Merck’s Life Science business MilliporeSigma has opened two new messenger ribonucleic acid (mRNA) drug substance manufacturing facilities in Germany.

Developed with an investment of €28m ($29.57m), the new Good Manufacturing Practices (GMP)-grade sites are located in Darmstadt and Hamburg and form part of the company’s ongoing investment of €1bn to advance mRNA technologies.

The two facilities, which created 75 new jobs, offer mRNA services at all scales and applications, from pre-clinical to commercial.

The services consist of analytical development and biosafety testing for mRNA technologies.

The company’s Millipore contract testing, development and manufacturing organisation (CTDMO) services now consist of all crucial stages of mRNA technologies, lipids, lipid nanoparticles (LNP) and fill/finish, including key products and biosafety testing.

These services are part of the Life Science Services business division.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company also provides differentiated PCR-based technology for clinical as well as commercial mRNA manufacturing.

Merck Life Science business sector’s Life Science Services head Dirk Lange stated: “mRNA has emerged as the breakthrough technology of this century, providing great promise to not only treat, but potentially cure, a wide array of diseases such as cancer, heart disease and muscular dystrophy.

“We are now the first CTDMO to streamline the entire mRNA process for our clients.”

The company delivers mRNA, custom and portfolio lipids, LNP and fill/finish CTDMO services through its sites in Darmstadt and Hamburg, Schaffhausen, Switzerland, and Indianapolis, US.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.